Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (5494)	8/6/1999 2:35:00 PM
From: Mohan Marette	Respond to of 12475

Ranbaxy scrip soars 50% in a month, sees huge volumes ranbaxy.com Our Mumbai Bureau 5 AUGUST THE RANBAXY Laboratories scrip went ballistic on Thursday, touching an all-time high of Rs 1,024.80 on the Bombay Stock Exchange, and taking the market capitalisation of the pharma major to Rs 12,031 crore as against Rs 8,182 crore a month ago.The counter's temperature has been rising for a month now on anticipation of Ranbaxy announcing a deal with Bayer AG of Germany under which it will provide the latter a novel drug delivery system (NDDS) form of ciprofloxacin. When contacted, the company spokesperson said there was no announcement to be made today. Sources added that an announcement was likely in the next ten days. On the Bombay Stock Exchange, the scrip has gained a massive 47 per cent in the last one month, from Rs 687.60 on July 6 to Rs 1,011 on August 5. Daily volumes on the two exchanges combined touched 53.89 lakh on Thursday, the eighth time it has crossed the 45-lakh mark in the last month. Today's transactions represent 4.5 per cent of the company's equity capital. The Economic Times had broken the news of the deal on June 12 and June 26, and at that point sources estimated the magnitude of payments from Bayer to Ranbaxy at over $100m. This was made up of an upfront payment and 'milestone' payments when the product successfully went through stages of development aggregating $45m, and royalties on actual sales amounting to $40m a year from 2002. It was also mentioned then that actual announcement of the deal would be made only after two months. At present, there are several big speculations in the market about the value of the deal, with some putting it at $80m. The figure is likely to lend a major upside to the stock as the company's nine-month net profit last year was $27m. While Ranbaxy is all set to take advantage of the ciproflxacin going off patent in 2003, Bayer, the patent owner, is desperate for something that will give its own generic version an edge over all others. The NDDS form of ciprofloxacin is understood to be a single dose a day as against the conventional 2-3 times-a-day dosage. Ranbaxy plans brand-driven strategy for global operation - ET Online, June 10, 1999 economictimes.com

To: Mohan Marette who wrote (5494)	8/6/1999 2:43:00 PM
From: JPR	Read Replies (2) \| Respond to of 12475

Mohan: If the statement is coming from him & attributed correctly to yusuf khan alias dilip kumar, what he said does not go well with the Indians. To be generous to him, could it possible that he meant the following - If it is not for pakistan, we would not have lost our soldiers and Rs.500 crore. Am I being naive? Coming to Fernandes, his loose tongue and tongue-lashing needs a surgical correction known as tongue-tie - (tongue-in-cheek).<VBG> JPR